10/7/2024

Albuterol sulfate and Ipratropium Bromide Inhalation Solution

Products Affected - Description

- Albuterol sulfate and ipratropium bromide inhalation solution, Cipla USA, 3 mg / 0.5 mg, 3 mL 60 vials per carton NDC 69097-0840-64 - discontinued
- Albuterol sulfate and ipratropium bromide inhalation solution, Cipla USA, 3 mg / 0.5 mg, 3 mL 30 vials per carton NDC 69097-0840-53 - discontinued
- Albuterol sulfate and ipratropium bromide inhalation solution, Cipla USA, 3 mg/ 0.5 mg, 3 mL 30 vials per carton/5 vials per foil pouch NDC 69097-0173-53
- Albuterol sulfate and ipratropium bromide inhalation solution, Ritedose, 3 mg / 0.5 mg, 3 mL 60 vials per carton/30 vial per foil pouch NDC 76204-0600-60
- Albuterol sulfate and ipratropium bromide inhalation solution, Ritedose, 3 mg / 0.5 mg, 3 mL 30 vials per carton/1 vial per foil pouch NDC 76204-0600-01
- Albuterol sulfate and ipratropium bromide inhalation solution, Ritedose, 3 mg / 0.5 mg, 3 mL 30 vials per carton/30 vial per foil pouch NDC 76204-0600-30

Reason for the Shortage

- Cipla did not provide a reason for the shortage.
- Mylan has albuterol and ipratropium inhalation solution available.
- Nephron is shipping albuterol and ipratropium inhalation solution regularly. Nephron states demand has recently increased for product.
- Ritedose did not provide a reason for the shortage.
- Sun Pharma has albuterol and ipratropium inhalation solution available.

Available Products

- Albuterol sulfate and ipratropium bromide inhalation solution, Cipla USA, 3 mg / 0.5 mg, 3 mL 60 vials per carton NDC 69097-0173-64
- Albuterol sulfate and ipratropium bromide inhalation solution, Cipla USA, 3 mg / 0.5 mg, 3 mL 30 vials per carton NDC 69097-0840-87
- Albuterol sulfate and ipratropium bromide inhalation solution, Mylan (Viatris), 3 mg / 0.5 mg, 3 mL 30 vials per carton/30 vial per foil pouch NDC 00378-9671-30
- Albuterol sulfate and ipratropium bromide inhalation solution, Mylan (Viatris), 3 mg / 0.5 mg, 3 mL 60 vials per carton/30 vial per foil pouch NDC 00378-9671-60
- Albuterol sulfate and ipratropium bromide inhalation solution, Mylan (Viatris), 3 mg / 0.5 mg, 3 mL 30 vials per carton/1 vial per foil pouch NDC 00378-9671-93
- Albuterol sulfate and ipratropium bromide inhalation solution, Nephron Pharmaceuticals Corporation, 3 mg / 0.5 mg, 3 mL 30 vials per carton/5 vials per foil pouch NDC 00487-0201-03
- Albuterol sulfate and ipratropium bromide inhalation solution, Nephron Pharmaceuticals Corporation, 3 mg / 0.5 mg, 3 mL 30 vials per carton/1 vial per foil pouch NDC 00487-0201-01
- Albuterol sulfate and ipratropium bromide inhalation solution, Nephron Pharmaceuticals Corporation, 3 mg / 0.5 mg, 3 mL 60 vials per carton/5 vials per foil pouch NDC 00487-0201-60
- Albuterol sulfate and ipratropium bromide inhalation solution, Sun Pharma, 3 mg / 0.5 mg, 3 mL 30 vials per carton NDC 47335-0756-49
- Albuterol sulfate and ipratropium bromide inhalation solution, Sun Pharma, 3 mg / 0.5 mg, 3 mL 60 vials per carton NDC 47335-0756-52

Estimated Resupply Dates

- Cipla has albuterol and ipratropium 3 mL inhalation solution in 30 count (5 vials per pouch) available with short expiration dating.
- Ritedose has all albuterol and ipratropium inhalation solution presentations in limited supply.

Updated

Updated October 7, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 13, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.